Galderma Pioneers NDA Path Into OTC Acne Treatment Market
This article was originally published in The Rose Sheet
FDA on July 8 announces approval for Galderma Laboratories to market Differin Gel 0.1% (adapalene) as an OTC, once-daily topical acne treatment for consumers 12 years old and up.
You may also be interested in...
After working hard to turnaround its troubled Skin Health dermatology operation, Nestlé looks set to offload the business to a consortium of private-equity buyers. The consortium - led by EQT - have identified expansion in the US consumer health market as an immediate priority.
While FDA does not identify specific product types on the agenda for its public workshop on approaches in skin toxicity testing for topical drug products, advocacy and trade groups anticipate sunscreen ingredient testing could be among the discussion topics. Product expansions have been stifled by regulatory concerns, drawing particular attention from the public health community.
If approved by FDA, the product, to be marketed as Differin Gel, would be the first OTC drug available in the US that contains an ingredient in the retinoid class – adapalene 0.1 gel. Discussion at the April 15 meeting of FDA's Nonprescription Drugs Advisory Committee focused largely on the issue of self-selection among pregnant women.